HeartBeam, Inc. (BEAT) - 10-Q Summary
Business Context and Reporting Period
HeartBeam, Inc. is a medical technology company developing ambulatory cardiac monitoring solutions, specifically a 3D ECG platform. This report covers the quarterly period ended June 30, 2026. The Company operates as a single segment and is classified as a smaller reporting company and an emerging growth company. As of June 30, 2026, the Company had 16 employees.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(9.7 million) | $(10.5 million) |
| Operating Expenses | $9.8 million | $10.5 million |
| Cash and Cash Equivalents (Ending) | $8.7 million | $3.3 million |
| Net Cash Used in Operating Activities | $(7.0 million) | $(7.9 million) |
| Net Cash Provided by Financing Activities | $11.8 million | $10.7 million |
| Total Liabilities | $2.5 million | $3.2 million |
| Stockholders' Equity | $8.2 million | $4.2 million |
Note: The filing does not provide gross margin or operating margin data as there is no revenue.
Material Changes vs. Prior Period
- Capital Raise: In April 2026, the Company completed an underwritten public offering of 14,375,000 shares (including full exercise of the overallotment option), raising approximately $11.5 million in gross proceeds ($10.3 million net). Additionally, $1.5 million was raised via the At-The-Market (ATM) program.
- Expense Reduction: Total operating expenses decreased by 7% ($0.7 million) compared to the prior six-month period. Research and Development (R&D) expenses dropped 31% ($2.1 million) due to reduced product development costs and lower stock-based compensation.
- SG&A Increase: Selling, General, and Administrative (SG&A) expenses increased 37% ($1.4 million) year-over-year. This was driven by one-time non-cash stock-based compensation ($0.6 million) and severance accruals ($0.3 million) related to the departure of the former CEO.
- Liquidity: Cash balances increased by $4.3 million to $8.7 million, primarily due to the equity financing activities.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management states that existing liquidity is insufficient to fund operations for the next twelve months. This raises substantial doubt about the Company's ability to continue as a going concern. Continued operations depend on raising additional capital.
- Revenue Outlook: The Company expects no material commercial revenue in 2026. A limited commercial launch has begun with partners ClearCardio and Atelier Health, but definitive agreements are still being negotiated.
- Strategic Shift: The Company is pivoting to license its 3D ECG signal technology to third-party AI platforms and partners rather than focusing solely on direct device sales. It is also advancing a 12-Lead Patch prototype.
- Leadership Changes: Robert P. Eno departed as CEO and Board member effective June 30, 2026. Branislav Vajdic (President) assumed the role of Principal Executive Officer. Mark Strome resigned from the Board.
- Nasdaq Compliance: The Company received a deficiency letter from Nasdaq regarding its stock price falling below the $1.00 minimum bid requirement. It has 180 days (until December 29, 2026) to regain compliance.
- Unusual Items: Significant one-time expenses included the acceleration of stock awards and severance for the former CEO. A performance-based restricted stock unit (PRSU) award of 2.8 million shares was granted to the President.
Investor Verification Checklist
- Verify the timeline and terms of the definitive commercial agreements with ClearCardio and Atelier Health to assess revenue potential.
- Monitor the Company's progress in raising additional capital to address the "substantial doubt" regarding going concern status.
- Track the stock price to ensure compliance with Nasdaq listing requirements by the December 2026 deadline.
- Review the results of the ALIGN-ACS pilot study and the 12-Lead Patch pilot study for regulatory pathway validation.
- Assess the impact of the strategic shift toward technology licensing on the Company's long-term valuation model.